241 related articles for article (PubMed ID: 33601375)
1. Identification of Biomarkers in Patients with Thrombotic Thrombocytopenic Purpura Presenting with Large and Small Ischemic Stroke.
Lin C; Memon R; Sui J; Zheng XL
Cerebrovasc Dis Extra; 2021; 11(1):29-36. PubMed ID: 33601375
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.
Sui J; Cao W; Halkidis K; Abdelgawwad MS; Kocher NK; Guillory B; Williams LA; Gangaraju R; Marques MB; Zheng XL
Blood Adv; 2019 Dec; 3(24):4177-4186. PubMed ID: 31856267
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.
Sui J; Lu R; Halkidis K; Kocher NK; Cao W; Marques MB; Zheng XL
J Thromb Haemost; 2021 Feb; 19(2):370-379. PubMed ID: 33188723
[TBL] [Abstract][Full Text] [Related]
4. Immune-Thrombotic Thrombocytopenic Purpura is a Rare Cause of Ischemic Stroke in Young Adults: Case Reports and Literature Review.
Tomich C; Debruxelles S; Delmas Y; Sagnier S; Poli M; Olindo S; Renou P; Rouanet F; Sibon I
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3163-3171. PubMed ID: 30217637
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
Mancini I; Ferrari B; Valsecchi C; Pontiggia S; Fornili M; Biganzoli E; Peyvandi F;
Eur J Intern Med; 2017 Apr; 39():79-83. PubMed ID: 27887777
[TBL] [Abstract][Full Text] [Related]
6. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
Pascual-Izquierdo C; Del Rio-Garma J; de la Rubia J; Viejo A; Mingot E; Cid J; Solanich X; Fernández-Sojo J; Martín-Sánchez J; Hernández L; García-Gala JM; Alonso N; González V; Oliva A; Gómez-Seguí I; Goterris R; Guerra L; García-Candel F; Fernández-Docampo M; Antelo ML; Salgado-Barreira Á; Salinas R;
J Clin Apher; 2021 Aug; 36(4):563-573. PubMed ID: 33780553
[TBL] [Abstract][Full Text] [Related]
7. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
Roose E; Schelpe AS; Tellier E; Sinkovits G; Joly BS; Dekimpe C; Kaplanski G; Le Besnerais M; Mancini I; Falter T; Von Auer C; Feys HB; Reti M; Rossmann H; Vandenbulcke A; Pareyn I; Voorberg J; Greinacher A; Benhamou Y; Deckmyn H; Fijnheer R; Prohászka Z; Peyvandi F; Lämmle B; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
Blood; 2020 Jul; 136(3):353-361. PubMed ID: 32356859
[TBL] [Abstract][Full Text] [Related]
8. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
Yue C; Su J; Fan X; Song L; Jiang W; Xia J; Shi T; Zhang X; Li X
Orphanet J Rare Dis; 2020 Aug; 15(1):225. PubMed ID: 32859237
[TBL] [Abstract][Full Text] [Related]
9. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of thrombotic thrombocytopenic purpura: easy-to-use fiber optic surface plasmon resonance immunoassays for automated ADAMTS-13 antigen and conformation evaluation.
Bonnez Q; Dekimpe C; Bekaert T; Tellier E; Kaplanski G; Joly BS; Veyradier A; Coppo P; Lammertyn J; Tersteeg C; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2024 Jul; 22(7):1936-1946. PubMed ID: 38554935
[TBL] [Abstract][Full Text] [Related]
11. Cerebral Infarction in Immune Thrombotic Thrombocytopenic Purpura Is Associated with Old Age, Hypertension, Smoking, and Anti-ADAMTS13 Ig, But Not with Mortality.
Memon R; Sui J; Lin C; Zheng XL
TH Open; 2021 Jan; 5(1):e1-e7. PubMed ID: 33458563
[No Abstract] [Full Text] [Related]
12. Thrombotic thrombocytopenic purpura: The role of ADAMTS13.
Rogers HJ; Allen C; Lichtin AE
Cleve Clin J Med; 2016 Aug; 83(8):597-603. PubMed ID: 27505881
[TBL] [Abstract][Full Text] [Related]
13. Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.
Dekimpe C; Roose E; Tersteeg C; Joly BS; Dewaele A; Horta S; Pareyn I; Vandenbulcke A; Deckmyn H; Feys HB; Tellier E; Kaplanski G; Scully M; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
J Thromb Haemost; 2020 Apr; 18(4):985-990. PubMed ID: 31989742
[TBL] [Abstract][Full Text] [Related]
14. ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura.
Sakai K; Matsumoto M; De Waele L; Dekimpe C; Hamada E; Kubo M; Tersteeg C; De Meyer SF; Vanhoorelbeke K
Blood Adv; 2023 Jan; 7(1):131-140. PubMed ID: 36306339
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
Velásquez Pereira LC; Roose E; Graça NAG; Sinkovits G; Kangro K; Joly BS; Tellier E; Kaplanski G; Falter T; Von Auer C; Rossmann H; Feys HB; Reti M; Prohászka Z; Lämmle B; Voorberg J; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
J Thromb Haemost; 2021 Feb; 19(2):478-488. PubMed ID: 33171004
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
Mariotte E; Azoulay E; Galicier L; Rondeau E; Zouiti F; Boisseau P; Poullin P; de Maistre E; Provôt F; Delmas Y; Perez P; Benhamou Y; Stepanian A; Coppo P; Veyradier A;
Lancet Haematol; 2016 May; 3(5):e237-45. PubMed ID: 27132698
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.
Staley EM; Cao W; Pham HP; Kim CH; Kocher NK; Zheng L; Gangaraju R; Lorenz RG; Williams LA; Marques MB; Zheng XL
Haematologica; 2019 Jan; 104(1):166-175. PubMed ID: 30171022
[TBL] [Abstract][Full Text] [Related]
18. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
[TBL] [Abstract][Full Text] [Related]
19. ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.
Sui J; Zheng L; Zheng XL
Arch Pathol Lab Med; 2023 Aug; 147(8):974-979. PubMed ID: 36223210
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age.
Rottenstreich A; Dor S; Keren-Politansky A; Sarig G; Nadir Y; Ellis M; Spectre G; Kirgner I; Pikovsky O; Arad A; Dann EJ; Kalish Y
J Thromb Thrombolysis; 2021 Jan; 51(1):187-193. PubMed ID: 32388825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
